Life Science Company News

C-RAD publishes outcome of Employee Warrant Program 2018/2021

C-RAD has launched a warrant program for its employees. All warrants that were offered to current employees were subscribed for.

The Annual Shareholder Meeting decided in May 2018 to issue 100,000 warrants for the purpose of using them as part of an employee incentive program for C-RAD AB. 90,000 warrants were initially offered to employees and 10,000 were issued to C-RAD Positioning AB, with permission for these to be transferred on one or more occasions to current or future employees.

Current employees of the entire C-RAD group signed up for a total of 90,000 warrants or 100% of the allotted amount. Members of the management team of C-RAD AB and C-RAD Positioning, together with key employees, have signed up for 72,000 warrants.

C-RAD will not issue new press releases if further warrants are offered and signed up for within this warrant program.

“This result speaks very positively for the company and its team,” says Tim Thurn, CEO of C-RAD. “The commitment as well as the expectations that the management team and employees have regarding the development of the company can be visualized by the interest they have shown in the warrant program. This is an excellent mechanism for aligning the interests of our employees with those of our shareholders.”

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit www.c-rad.com

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com

The information was submitted for publication at 08:30 CEST on June 19, 2018.

Attachment

By: Nasdaq / GlobeNewswire - 19 Jun 2018
Back to overview

Enhance your business development with Biotechgate